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Emerging resistance phenotypes and antimicrobial resistance rates among pathogens recovered from commu-
nity-acquired urinary tract infections (CA-UTI) is an increasing problem in specific regions, limiting therapeutic
options.
As part of the SENTRY Antimicrobial Surveillance Program, a total of 611 isolates were collected in 2003 from
patients with CA-UTI presenting at Latin American  medical centers. Each strain was tested in a central laboratory
using Clinical Laboratory Standard Institute (CLSI) broth microdilution methods with appropriate controls.
 Escherichia coli was the leading pathogen (66%), followed by Klebsiella spp. (7%), Proteus mirabilis (6.4%),
Enterococcus spp. (5.6%), and Pseudomonas aeruginosa (4.6%). Surprisingly high resistance rates were recorded
for E. coli against first-line orally administered agents for CA-UTI, such as ampicillin (53.6%), TMP/SMX (40.4%),
ciprofloxacin (21.6%), and gatifloxacin (17.1%). Decreased susceptibility rates to TMP/SMX and ciprofloxacin
were also documented for Klebsiella spp. (79.1 and 81.4%, respectively), and P. mirabilis (71.8 and 84.6%, respec-
tively). For Enterococcus spp., susceptibility rates to ampicillin, chloramphenicol, ciprofloxacin, and vancomycin
were 88.2, 85.3, 55.9, and 97.1%, respectively. High-level resistance to gentamicin was detected in 24% of Entero-
coccus spp. Bacteria isolated from patients with CA-UTI in Latin America showed limited susceptibility to orally
administered antimicrobials, especially for TMP/SMX and fluoroquinolones. Our results highlight the need for
developing specific CA-UTI guidelines in geographic regions where elevated resistance to new and old compounds
may influence prescribing decisions.
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Community-acquired urinary tract infections (CA-
UTI) are a frequent problem worldwide. In the United
States, surveys have estimated an incidence of eight
million UTI episodes per year (Foxman 2002). These
infections are usually caused by Escherichia coli, but
other uropatho-gens, such as Klebsiella spp. and Sta-
phylococcus saprophyticus, have also been frequently
isolated (Ronald 2002, Lau et al. 2004).
Effective management of UTIs in the outpatient set-
ting has been hampered by the fact that many strains
have developed resistance to several oral antimicrobial
agents. The increasing frequency of thrimetoprim/
sulfamethoxazole (TMP-SMX) resistance is worrisome,
since this agent is frequently prescribed for uncompli-
cated UTIs in many developed and developing countries
(Talan et al. 2000, Hay et al. 2005, Sader et al. 2005). Re-
ports from North America indicate an elevated prevalence
of TMP-SMX-resistant isolates in this region associated
with increased clinical failure rates (Manges et al. 2004).
Although the Infectious Diseases Society of America
(IDSA) guidelines and some studies have suggested that
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fluoroquinolones may be used as first-line therapy for
treatment of uncomplicated bacterial cystitis in woman
(Warren et al. 1999,Talan et al. 2004) reports of uro-
pathogens resistant to these agents have increasingly been
reported (Alos et al. 2005).
The continuous trend of empirically treating CA-UTI
episodes poses a great challenge for researchers, since
data on uropathogens prevalence and antimicrobial sus-
ceptibility have been increasingly more difficult to ob-
tain. Moreover, regional variations in resistance patterns
do occur, and must be as well documented (Gupta 2003).
In Latin America, few data are available on the frequency
and resistance rates of CA-UTI. In this study, we have
evaluated the pathogen frequency and susceptibility pat-
terns of CA-UTI in Latin American medical centers as part
of the SENTRY Antimicrobial Surveillance Program.
MATERIALS  AND  METHODS
Bacterial strains - Each medical center was respon-
sible to collect consecutive isolates from CA-UTI, includ-
ing urinary pathogens from patients presenting to outpa-
tient clinics or emergency department. Urinary specimens
were collected in the course of routine clinical manage-
ment, and infections were considered to be clinically sig-
nificant and of community origin by local criteria. A num-
ber of demographic information, such as antibiotic use,
and presence of complicated UTI, were not collected or
might have not been available. A total of 611 non-dupli-
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cate bacterial isolates were collected from patients with
CA-UTI presenting at Latin America medical centers par-
ticipating in the SENTRY Program between January and
December 2003 (Argentina, Chile, Brazil, Mexico, and Ven-
ezuela). All isolates were identified at the participating
institution by the routine methodology in use at each labo-
ratory. Upon receipt at the monitoring laboratory (JMI
Laboratories, North Liberty, IA, US), isolates were sub-
cultured onto blood agar to ensure viability and purity.
Confirmation of species identification was performed with
Vitek (bioMérieux Vitek, St Louis, MO) or conventional
methods as required.
Participant medical centers - The medical centers
were located in San Isidro and Buenos Aires (Argentina);
Brasília, Florianópolis, Porto Alegre, São Paulo (Brazil);
Santiago (two medical centers, Chile); Ciudade del Mexico,
(Mexico); and Caracas (Venezuela).
Susceptibility testing - Antimicrobial susceptibility
testing was performed and interpreted following the guide-
lines for reference broth microdilution method described
by the Clinical and Laboratory Standards Institute (CLSI,
formerly  National Committee for Clinical and Laboratory
Standards) (NCCLS 2003). The minimal inhibitory concen-
trations (MICs) were defined as the lowest antimicrobial
concentration able to totally inhibit bacterial growth. The
diverse antimicrobial agent powders were obtained from
the respective manufacturers or purchased from Sigma
(St Louis, MO, US). Dry-form microdilution panels and
broth for inoculation were purchased from Trek Diagnos-
tic Systems (Westlake, OH, US). Testing of quality con-
trol strains E. coli ATCC 25922 and 35218, S. aureus ATCC
29213, P. aeruginosa ATCC 27853, and Enterococcus
faecalis ATCC 29212 was performed for quality assur-
ance purposes. Isolates of E. coli and K. pneumoniae
with increased MIC values (≥ 2 µg/ml) for ceftazidime and/
or ceftriaxone and/or aztreonam were considered as pos-
sible extended-spectrum β-lactamase (ESBL)-producing
phenotypes according to CLSI criteria (2005). Production
of ESBL was confirmed by disk-approximation test
(Thomson & Sanders 1992).
RESULTS AND DISCUSSION
E. coli (66%) was the most common pathogen iso-
lated from CA-UTI in Latin American countries, followed
by P. mirabilis (6.4%) and K. pneumoniae (5.9%) (Table
I). Enterococcus spp. was the most common gram-posi-
tive uropathogen, responsible for 5.6% of all CA-UTI.
These data are similar to those presented by other sur-
veillance studies, in which gram-negative agents were the
most common pathogens associated with CA-UTI (Zhanel
et al. 2000, Kahlmeter 2003).
Overall, the majority of isolates (75.6%) were collected
from female patients with E. coli being also the most com-
mon uropathogen (Table II). The median age of patients
with CA-UTI was similar in both groups: 41.4 years (fe-
male sex) and 43.7 years (male sex) (data not shown). The
predominance of E. coli as the leading agent of CA-UTI
in women had been also verified by other surveillance
reports from distinct geographic regions, such as the ECO
SENS report from Europe and Canada, and  the TSN study
from the United States (Kahlmeter 2000, Gupta et al. 2001).
Among gram-positive uropathogens, Enterococcus
spp. and group B streptococci were the most common
agents isolated from women, responsible for 5.2 and 2.8%,
respectively, of all CA-UTI (Table II). In this study, how-
ever, only 8 isolates of S. saprophyticus were recovered.
These results contrast with other reports, where S.
saprophyticus remains a significant pathogen causing
CA-UTI in women (Kahlmeter 2003, Muratani &
Matsumoto 2004). This finding may indicate a distinct
pattern of Gram-positive uropathogen distribution in the
Latin American region.
The antimicrobial susceptibility results of the most
frequent pathogens associated with CA-UTI in Latin
America is shown in Table III. The β-lactam agents
ceftriaxone (MIC50, ≤ 0.25 µg/ml), ceftazidime (MIC50, ≤ 1
µg/ml), and cefepime (MIC50, ≤ 0.12 µg/ml), displayed ex-
cellent activity against E. coli (98.3-98.5% susceptible).
All of the 403 clinical isolates of E. coli were susceptible
to imipenem and meropenem, indicating that carbapenem
resistance is still an unusual phenotype among Entero-
bacteriaceae isolated from CA-UTI in the region. On the
other hand, decreased susceptibility rates were detected
among E. coli for common orally administered agents, such
as ampicillin (46.2% susceptible), ciprofloxacin (77.4%
susceptible), and TMP-SMX (59.6% susceptible). In fact,
among the orally prescribed agents, cefuroxime (2.2% re-
sistant), amoxicillin/clavulanate (1.2% resistant), and ni-
trofurantoin (6.9% resistant) achieved the lowest resis-
tance rates for E. coli.
Our study have  detected much higher resistance rates
when compared to the ECO SENS and TSN Programs for
some oral prescribed agents (Gupta et al. 2001, Kahlmeter
2003). Most surprisingly, the E. coli resistance rates found
in the current study are even higher than those described
by some surveillance programs evaluating hospitalized
patients. The EARSS study in Spain reported lower resis-
tance rates to ciprofloxacin (19.3%), and TMP/SMX
(32.6%), among E. coli strains from Spanish hospitals
(Oteo et al. 2005). The current study showed similar sus-
ceptibility rates for some orally prescribed agents among
TABLE I
Occurrence of the top ten pathogens isolated from
community-acquired urinary tract infections in Latin American
medical centers (SENTRY Antimicrobial Surveillance
Program 2003)
Organism or group No. of isolates (%)
Escherichia coli 403 (66)
Klebsiella spp. 43 (7)
Proteus mirabilis    39 (6.4)
Enterococcus spp.    34 (5.6)
Pseudomonas aeruginosa    28 (4.6)
Group B streptococci    14 (2.3)
Staphylococcus saprophyticus      8 (1.3)
Klebsiella oxytoca      7 (1.1)
Enterobacter cloacae  6 (1)
Serratia marcescens      5 (0.8)
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CA-UTI isolates similar to those showed by E. coli
strains from other infection sites previously evaluated
by the SENTRY Program in Latin America, such as
bloodstream infections (Sader et al. 2002), and hospital-
acquired UTI (Gales et al. 2002).
The increased resistance rates detected for TMP/SMX
in Latin America is of great concern. These rates may re-
flect a possible widespread use of this low cost antimicro-
bial agent for treatment of CA-UTI in the region, or as a
prophylactic agent against Pneumocystis jiroveci infec-
tions in the HIV-infected population.
Increased resistance rates of E. coli against the stud-
ied quinolones were also verified in contrast to other sur-
veillance studies evaluating CA-UTI in United States and
Europe, which have documented resistance rates of ap-
proximately 2% (Gupta et al. 2001, Kahlmeter 2003) for
some fluoroquinolones (Table III). In fact, the suscepti-
bility rates to the fluoroquinolones were lower than those
observed for hospital-acquired E. coli isolates previously
collected by the SENTRY in Latin America (Gales et al.
2002). These increased resistance rates among commu-
nity-acquired E. coli was addressed by the EARSS study
in Spain, where 19.3% of all invasive clinical isolates evalu-
ated in 2003 were resistant to ciprofloxacin (Oteo et al.
2005). These high resistance rates were attributed to an
increase in fluoroquinolone consumption over the years
in Spain. Prior exposure to fluoroquinolones has been re-
cently acknowledged to be an independent risk factor for
ciprofloxacin-resistant E. coli from CA-UTI (Killgore et al.
2004).
Among the participating countries, Brazil and Chile
displayed the highest susceptibility rates to the evalu-
ated fluoroquinolones against E. coli (Table IV). Although
Mexico contributed with only 36 E. coli isolates, very low
susceptility rates were detected among all tested oral
agents. Overall, rates of TMP/SMX resistance were sig-
nificantly decreased for all Latin American countries. The
current data may reflect the increased use of orally pre-
scribed agents in some Latin American countries, to treat
hospital or community-acquired infections, such as UTI
or respiratory tract infections. This overuse may select
for multidrug-resistant E. coli phenotypes, harboring the
potential to disseminate within a specific region. Further
antimicrobial consumption studies at community level are
needed in the Latin American region to verify this as-
sumption.
High resistance rates were also documented for TMP/
SMX among the other Enterobacteriaceae causing CA-
UTI, ranging from 19.4% for K. pneumoniae, to 28.2% for
P. mirabilis (Table III). Resistance rates for the tested
fluoroquinolones were lower than those described for E.
coli, but also significantly elevated. Overall, more than
85% of clinical isolates of K. pneumoniae and P. mirabilis
were susceptible to third- and fourth-generation cepha-
losporins. No isolate was found to be resistant to imipenem
or meropenem. These two Enterobacteriaceae pathogens
have been described as frequent uropathogens associ-
ated with CA-UTI among non-E. coli isolates, especially
among adult and elderly patients (Gupta et al. 2001). Other
surveillance studies, however, have found distinct and
much lower resistance rates for orally administered anti-
microbial agents for these pathogens (Gupta et al. 2001,
Kahlmeter 2003).
A total of 88.2% of Enterococcus spp. isolates were
susceptible to ampicillin (Table III). Among other orally
administered agents, nitrofurantoin (94.1%) and chloram-
phenicol (85.3%) demonstrated the higher susceptibility
rates. Linezolid was the only agent able to inhibit the
growth of 100% of all Enterococcus spp. isolates, and
2.9% of isolates were resistant to both, teicoplanin and
vancomycin (vanA phenotype). The majority of group B
streptococci collected from CA-UTI were susceptible to
the tested antimicrobial agents, including the tested
fluoroquinolones.
Surprisingly, a total of 28 isolates of P. aeruginosa
were reported (Table III). Previous surveillance studies
have also documented P. aeruginosa among patients with
CA-UTI (Barrett et al. 1999, Lau et al. 2004). These data
may correspond, in the current study, to infections devel-
oped in the community setting from patients with recent
hospitalization and/or antimicrobial treatment.
Rates of ESBL-producing isolates were 1.7, 16.3, and
5.1%, respectively, for E. coli, Klebisella spp., and P.
mirabillis (data not shown). The increasing frequency of
TABLE II
Occurrence of the top five pathogens isolated from community-acquired urinary tract infections in Latin American medical centers
according to gender distribution (SENTRY Antimicrobial Surveillance Program 2003)
Organism or group (%)
Gender
Female (n = 462) Male  (n = 148)
1 Escherichia coli (71.6) Escherichia coli (48.0)
2 Proteus mirabilis (5.4) Pseudomonas aeruginosa (11.5)
3 Klebsiella pneumoniae (5.2) Proteus mirabilis (9.5)
Enterococcus spp. (5.2)
4 Group B streptococcus (2.8) Klebsiella pneumoniae (8.1)
5 Pseudomonas aeruginosa (2.4) Enterococcus faecalis (6.8)
Gender information was not available for one patient.
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TABLE III
Antimicrobial susceptibility of community-acquired urinary tract infection isolates collected from Latin American medical centers
(SENTRY Antimicrobial Surveillance Program 2003)
MIC50 MIC90 % susceptible % resistant
Escherichia coli (n = 403)
Ampicillina > 16 > 16   46.2 53.6
Ampicillin/sulbactam      8    32   56.6 23.3
Amoxicillin/clavulanatea      8    16   83.6   1.2
Piperacillin/tazobactam      2      4   97.3   0.2
Cefoxitin      4      8   93.1   1.7
Cefuroximea      4      8   76.4   2.2
Ceftriaxone       ≤ 0.25        ≤ 0.25   98.5   1.2
Ceftazidime  ≤ 1   ≤ 1    98.3   1.5
Cefepime       ≤ 0.12        ≤ 0.12   98.8   1.0
Aztreonam       ≤ 0.12        ≤ 0.12   98.3   1.7
Imipenem     ≤ 0.5     ≤ 0.5 100.0   0.0
Amikacin      2      4 100.0   0.0
Gentamicin   ≤ 2      4   90.1   8.4
Nalidixic acida      4 > 32   72.7 29.3
Ciprofloxacina        ≤ 0.03   > 4   77.4 21.6
Gatifloxacina        ≤ 0.03   > 4   79.2 17.1
Levofloxacina        ≤ 0.03   > 4   78.7 18.6
Nitrofurantoina ≤ 16    32   93.1     6.9b
Trimethoprim/sulfamethoxazolea      ≤ 0.5   > 2   59.6 40.4
Klebsiella spp. (n = 43)
Ampicillina > 16 > 16     9.3 74.4
Ampicilllin/sulbactam      8 > 32   67.4 25.6
Amoxicillin/clavulanatea      2    16   76.7   7.0
Piperacillin/tazobactam      2     32   88.4   9.3
Cefuroximea      2 > 16   74.4 16.3
Ceftriaxone        ≤ 0.25     32   86.0   9.3
Ceftazidime   ≤ 1    16   88.4   4.7
Cefepime        ≤ 0.12      2   90.7   7.0
Aztreonam        ≤ 0.12 > 16   83.7 11.6
Imipenem      ≤ 0.5     ≤ 0.5 100.0   0.0
Amikacin      2    16   95.3   4.7
Gentamicin   ≤ 2   > 8   86.0 14.0
Nalidixic acida      4 > 32   74.4 25.6
Ciprofloxacina           0.12   > 4   81.4 18.6
Gatifloxacina           0.06   > 4   83.7 16.3
Levofloxacina           0.06   > 4   81.4 16.3
Nitrofurantoina    32 > 32   51.2  48.8b
Trimethoprim/sulfamethoxazolea     ≤ 0.5   > 2   79.1 20.9
Proteus mirabilis (n = 39)
Ampicillina    ≤ 1 > 16   59.0 41.0
Ampicillin/sulbactama       1     32   76.9 10.3
Amoxicillin/clavulanatea    ≤ 1      8   94.9   0.0
Piperacillin/tazobactam      ≤ 0.5      1 100.0   0.0
Cefuroximea      2      8   89.7   7.7
Ceftriaxone        ≤ 0.25        ≤ 0.25   94.9   5.1
Ceftazidime   ≤ 1   ≤ 1 100.0   0.0
Cefepime        ≤ 0.12         0.5   94.9   5.1
Aztreonam        ≤ 0.12        ≤ 0.12 100.0   0.0
Imipenem       1       2 100.0   0.0
Meropenem        ≤ 0.06        ≤ 0.06 100.0   0.0
Amikacin       4      8   97.4   2.6
Gentamicin   ≤ 2   > 8   79.5 20.5
Nalidixic acida      4 > 32   84.6 15.4
Ciprofloxacina        ≤ 0.03      4   84.6 10.3
Gatifloxacina           0.12      4   87.2   7.7
Levofloxacina           0.06      2   92.3   5.1
Nitrofurantoina > 32 > 32    2.6   97.4b
Trimethoprim/sulfamethoxazolea     ≤ 0.5   > 2   71.8 28.2
!
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ESBL phenotypes in the community is an emerging prob-
lem (Pitout et al. 2005). Although we were not able to track
demographic data on these patients, risk factors for the
development of ESBL in the community have already been
described, including recent hospitalization, previous an-
timicrobial treatment, and use of immunosuppressive
therapy (Colodner et al. 2004). The current report further
emphasizes the importance of routine screening, by clini-
cal laboratories, of ESBL production among Enterobacte-
riaceae strains isolated from community-acquired infec-
tions.
In the Latin American region, international surveillance
programs have already documented increased resistance
rates for multiple pathogens among hospitalized patients
(Andrade et al. 2003, Gordon & Jones 2003, Mendes et al.
2005), probably reflecting local antimicrobial usage pat-
terns, leading to a high selective pressure, and/or dis-
semination of specific resistant clones. However, antimi-
crobial susceptibility among pathogens isolated from com-
munity-acquired infections is poorly investigated in this
region.
Although this is the first surveillance study in the
Latin American region to assess the frequency of patho-
gens from CA-UTI, a number of points should be raised.
The classification of CA-UTI was based on local criteria,
according to the study protocol, but some data, such as
previous hospitalization, may not have been available for
analysis. So, the presence of some pathogens, such as P.
aeruginosa and Enterococcus spp., and the low preva-
lence of S. saprophyticus, might reflect infections ac-
quired during hospitalization, followed by community-
onset after hospital discharge. However, a larger surveil-
lance study conducted in the US has also found even
elevated frequencies of Enterococcus spp. (from 5 to 12%)
and P. aeruginosa (from 1 to 4%) among CA-UTI in woman
(Gupta et al. 2001). Since most cases of CA-UTI are treated
empirically and cultures are not usually requested, we can
predict that some urine cultures evaluated in the present
Pseudomonas  aeruginosa (n = 28)
Ceftazidime      4 > 16     67.9  32.1
Cefepime      4 > 16     64.3  14.3
Aztreonam      8 > 16     57.1  39.3
Imipenem      1   > 8     71.4  25.0
Meropenem        0.5   > 8      71.4  14.3
Piperacillin/tazobactam      8 > 64      67.9 32.1
Amikacin     4 > 32      71.4  21.4
Gentamicin     4   > 8      60.7  35.7
Nalidixic acida,c > 32 > 32        3.6 96.4
Ciprofloxacina          0.25   > 4      67.9 32.2
Gatifloxacina      2   > 4      60.7  32.1
Levofloxacina       1   > 4      60.7  32.1
Nitrofurantoina,c > 32 > 32        0.0 100.0b
Polymyxin B    ≤ 1   ≤ 1      96.4    3.6
Enterococcus spp. (n = 34)
Ampicillina    ≤ 1 > 16      88.2  11.8
Chloramphenicola      8 > 16      85.3  11.8
Ciprofloxacina      1   > 4      55.9  35.3
Gatifloxacina         0.5   > 4      64.7  35.3
Levofloxacina      1   > 4      64.7  35.3
Linezolida   ≤ 2   ≤ 2    100.0    0.0
Nitrofurantoina ≤ 16 ≤ 16      94.1     5.9b
Quinupristin/Dalfopristin   ≥ 2   > 2      11.8  76.5
Gentamicin HL ≤ 500 > 1000      76.5  23.5
Streptomycin HL    ≤ 1000 > 2000      70.6  29.4
Teicoplanin     ≥ 2   ≥  2      97.1    2.9
Vancomycin     2    2      97.1    2.9
Group B streptococci (n = 14)
Ampicillina    ≤ 1    ≤ 1 100    0.1
Penicillina           0.06           0.06 100    0.0
Chloramphenicola   ≤ 2   ≤ 2 100    0.0
Clindamycina        ≤ 0.06        ≤ 0.06 100    0.0
Erythromycina        ≤ 0.06        ≤ 0.06      92.9    7.1
Gatifloxacina           0.25           0.25 100    0.0
Levofloxacina            0.25      1 100    0.0
Linezolida       1      1 100    0.0
Quinupristin/Dalfopristin        ≤ 0.25        ≤ 0.25 100    0.0
Vancomycin         0.5         0.5 100    0.0
a: orally administered antimicrobial agents; b: includes intermediate and resistant strains; c: susceptibility breakpoints for
Enterobacteriaceae were used (CLSI 2005).
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study were submitted to the laboratory because of treat-
ment failure or complicated UTI, and probably represent a
different patient population from those with first episode
of UTI. Although these limitations are inherent to the ret-
rospective nature of large surveillance studies, the inclu-
sion of such specimens may have overestimated the re-
sistance rates for some organisms.
Even tough, the decreased susceptibility rates found
for some agents in the current study is worrisome, since
some of them are currently prescribed as first-line agents
for treatment of CA-UTI in the Latin American region. As
most orally administered agents prescribed for CA-UTI
usually achieve high urinary concentrations, it was origi-
nally thought that in vitro resistance could not result into
therapeutic failure. However, recent studies have demon-
strated therapeutic failure in more than 50% of patients
infected with TMP/SMX-resistant uropathogens (Gupta
& Stamm 2002). The Infectious Diseases Society of
America (IDSA) guidelines consider TMP/SMX as the
current standard therapy for uncomplicated CA-UTI in
women (Warren et al. 1999). The IDSA guidelines recom-
mend that local antimicrobial susceptibility patterns of
community-acquired pathogens must be taken into ac-
count before prescribing such agents. As demonstrated
by this study, TMP/SMX may no longer be considered a
first-line orally administered agent for CA-UTI in the spe-
cific geographic regions covered by the SENTRY Program
in Latin America. Based on the results reported here, it
has become a difficult task to choose the most suitable
oral agent for empiric treatment of CA-UTI. Fluo-
roquinolones, agents recommended for communities
with elevated prevalence of TMP/SMX resistance, must
be used with caution, since resistance rates may reach up
to 21% among E. coli, as described in this study. Although
cefuroxime and amoxicillin/clavulanate demonstrated lower
resistance rates, β-lactam agents are less effective in
bacteriuria erradication, leading to increased rates of re-
currence (Daikos et al. 1987). Although nitrofurantoin
had poor activity against P. mirabilis and only 51.2% of
Klebsiella spp. were susceptible to this agent, it might
constitute a good alternative agent  for treatment of un-
complicated CA-UTI caused by E.coli.
The worldwide trend of empirically treating CA-UTI
may not apply for specific geographical regions in which
decreased susceptibility rates are documented for com-
mon uropathogens. In these communities with high rates
of antimicrobial resistance, routine urine cultures may be
necessary, since treatment failure is more likely to occur.
International guidelines may no longer be suitable for some
Latin American countries, where antimicrobial resistance
rates for first-line agents were unexpectedly elevated in
this study. The development of specific guidelines based
on local susceptibility patterns may be necessary in these
geographic regions. Continued surveillance programs,
such as the SENTRY, are essential to provide local infor-
mation for decision-makers and infectious diseases spe-
cialists developing CA-UTI guidelines.
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